ERBB2 and breast cancer: All toxicities were manageable; no treatment-related deaths or discontinuations were reported.<h4>Conclusion</h4>The 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer showed acceptable tolerability in Vietnamese patients, especially among younger, low-comorbidity Asian populations.